Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M.

J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.

PMID:
30523758
2.

CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.

Perea SE, Baladrón I, Valenzuela C, Perera Y.

Semin Oncol. 2018 Jan;45(1-2):58-67. doi: 10.1053/j.seminoncol.2018.04.006. Epub 2018 May 3. Review.

PMID:
30318085
3.

Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.

Cubillo A, Álvarez-Gallego R, Muñoz M, Pond G, Perea S, Sánchez G, Martin M, Rodríguez-Pascual J, Garralda E, Vega E, de Vicente E, Quijano Y, Muñoz C, Ugidos L, Toledo RA, Hidalgo M.

Am J Clin Oncol. 2019 Jan;42(1):56-59. doi: 10.1097/COC.0000000000000474.

PMID:
29975196
4.

Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.

Garay H, Espinosa LA, Perera Y, Sánchez A, Diago D, Perea SE, Besada V, Reyes O, González LJ.

J Pept Sci. 2018 Jun;24(6):e3081. doi: 10.1002/psc.3081. Epub 2018 Apr 20.

PMID:
29676523
5.

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.

Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, Otero Á, Albarran MI, Baños N, Durán Y, Bonilla V, Sarno F, Camacho-Artacho M, Sanchez-Perez T, Perea S, Álvarez R, De Martino A, Lietha D, Blanco-Aparicio C, Cubillo A, Domínguez O, Martínez-Torrecuadrada JL, Hidalgo M.

Clin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27.

PMID:
29588308
6.

Development and Validation of a Food Frequency Questionnaire to Estimate Intake among Children and Adolescents in Urban Peru.

Rodriguez CA, Smith ER, Villamor E, Zavaleta N, Respicio-Torres G, Contreras C, Perea S, Jimenez J, Tintaya K, Lecca L, Murray MB, Franke MF.

Nutrients. 2017 Oct 14;9(10). pii: E1121. doi: 10.3390/nu9101121.

7.

Evaluation of Two Dry Commercial Therapeutic Diets for the Management of Feline Chronic Gastroenteropathy.

Perea SC, Marks SL, Daristotle L, Koochaki PE, Haydock R.

Front Vet Sci. 2017 May 10;4:69. doi: 10.3389/fvets.2017.00069. eCollection 2017.

8.

The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.

Cirigliano SM, Díaz Bessone MI, Berardi DE, Flumian C, Bal de Kier Joffé ED, Perea SE, Farina HG, Todaro LB, Urtreger AJ.

Cancer Cell Int. 2017 Mar 31;17:42. doi: 10.1186/s12935-017-0413-y. eCollection 2017.

9.

Phylogeography and Conservation Genetics of the Ibero-Balearic Three-Spined Stickleback (Gasterosteus aculeatus).

Vila M, Hermida M, Fernández C, Perea S, Doadrio I, Amaro R, San Miguel E.

PLoS One. 2017 Jan 24;12(1):e0170685. doi: 10.1371/journal.pone.0170685. eCollection 2017.

10.

Ancient Mitochondrial Capture as Factor Promoting Mitonuclear Discordance in Freshwater Fishes: A Case Study in the Genus Squalius (Actinopterygii, Cyprinidae) in Greece.

Perea S, Vukić J, Šanda R, Doadrio I.

PLoS One. 2016 Dec 1;11(12):e0166292. doi: 10.1371/journal.pone.0166292. eCollection 2016.

11.

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.

Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M.

Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311.

12.

Evaluating aging in cats: How to determine what is healthy and what is disease.

Bellows J, Center S, Daristotle L, Estrada AH, Flickinger EA, Horwitz DF, Lascelles BD, Lepine A, Perea S, Scherk M, Shoveller AK.

J Feline Med Surg. 2016 Jul;18(7):551-70. doi: 10.1177/1098612X16649525. Review.

PMID:
27370393
13.

Aging in cats: Common physical and functional changes.

Bellows J, Center S, Daristotle L, Estrada AH, Flickinger EA, Horwitz DF, Lascelles BD, Lepine A, Perea S, Scherk M, Shoveller AK.

J Feline Med Surg. 2016 Jul;18(7):533-50. doi: 10.1177/1098612X16649523. Review.

PMID:
27370392
14.

What is healthy aging?

Perea S, Scherk M.

J Feline Med Surg. 2016 Jul;18(7):531. doi: 10.1177/1098612X16649522. No abstract available.

PMID:
27370391
15.

CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.

Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG.

Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1.

PMID:
27319334
16.

Cenozoic tectonic and climatic events in southern Iberian Peninsula: Implications for the evolutionary history of freshwater fish of the genus Squalius (Actinopterygii, Cyprinidae).

Perea S, Cobo-Simon M, Doadrio I.

Mol Phylogenet Evol. 2016 Apr;97:155-169. doi: 10.1016/j.ympev.2016.01.007. Epub 2016 Jan 16.

PMID:
26785110
19.

Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis.

Perera Y, Pedroso S, Borras-Hidalgo O, Vázquez DM, Miranda J, Villareal A, Falcón V, Cruz LD, Farinas HG, Perea SE.

Mol Cell Biochem. 2015 Jun;404(1-2):103-12. doi: 10.1007/s11010-015-2370-x. Epub 2015 Mar 25.

PMID:
25805179
20.

Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma.

Cabrales-Rico A, de la Torre BG, Garay HE, Machado YJ, Gómez JA, Audain E, Morales O, Besada V, Marcelo JL, Reyes V, Perera Y, Perea SE, Reyes O, González LJ.

J Pharm Biomed Anal. 2015 Feb;105:107-14. doi: 10.1016/j.jpba.2014.11.043. Epub 2014 Dec 3.

PMID:
25546027
21.

Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.

Perera Y, Toro ND, Gorovaya L, Fernandez-DE-Cossio J, Farina HG, Perea SE.

Mol Clin Oncol. 2014 Nov;2(6):935-944. Epub 2014 Jul 8.

22.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.

Estévez LG, Suarez-Gauthier A, García E, Miró C, Calvo I, Fernández-Abad M, Herrero M, Marcos M, Márquez C, Lopez Ríos F, Perea S, Hidalgo M.

Breast Cancer Res. 2014 Sep 4;16(4):R76. doi: 10.1186/bcr3695.

23.

Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.

Benavent Acero FR, Perera Negrin Y, Alonso DF, Perea SE, Gomez DE, Farina HG.

Mol Pharm. 2014 Jun 2;11(6):1798-807. doi: 10.1021/mp4006062. Epub 2014 Apr 28.

PMID:
24773585
24.

Spatial heterogeneity in the Mediterranean Biodiversity Hotspot affects barcoding accuracy of its freshwater fishes.

Geiger MF, Herder F, Monaghan MT, Almada V, Barbieri R, Bariche M, Berrebi P, Bohlen J, Casal-Lopez M, Delmastro GB, Denys GP, Dettai A, Doadrio I, Kalogianni E, Kärst H, Kottelat M, Kovačić M, Laporte M, Lorenzoni M, Marčić Z, Özuluğ M, Perdices A, Perea S, Persat H, Porcelotti S, Puzzi C, Robalo J, Šanda R, Schneider M, Šlechtová V, Stoumboudi M, Walter S, Freyhof J.

Mol Ecol Resour. 2014 Nov;14(6):1210-21. doi: 10.1111/1755-0998.12257. Epub 2014 Apr 15.

PMID:
24690331
25.

Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.

Cubillo A, Rodriguez-Pascual J, López-Ríos F, Plaza C, García E, Álvarez R, de Vicente E, Quijano Y, Hernando O, Rubio C, Perea S, Sanchez G, Hidalgo M.

Am J Clin Oncol. 2016 Jun;39(3):236-42. doi: 10.1097/COC.0000000000000045.

PMID:
24517959
26.

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT.

Oncotarget. 2014 Jan 15;5(1):258-63.

27.

Nutritional management of osteoarthritis.

Perea S.

Compend Contin Educ Vet. 2012 May;34(5):E4. Review.

PMID:
22581724
28.

Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.

Perera Y, Costales HC, Diaz Y, Reyes O, Farina HG, Mendez L, Gómez RE, Acevedo BE, Gomez DE, Alonso DF, Perea SE.

J Pept Sci. 2012 Apr;18(4):215-23. doi: 10.1002/psc.1432. Epub 2012 Mar 8.

PMID:
22407768
29.

Immunopharmacology 2011: an updated report of clinical achievements and perspectives.

Landys Chovel M, Perea S, de los Ángeles Robinson M, Rodeiro I, Delgado R, Ochoa RF, Hernández AM.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):693-5. doi: 10.1586/ecp.11.61.

PMID:
22111854
30.

Glutathione transferase pi (GSTpi) expression in breast cancer: an immunohistochemical and molecular study.

Jardim BV, Moschetta MG, Gelaleti GB, Leonel C, Regiani VR, de Santi Neto D, Bordin-Junior NA, Perea SA, Zuccari DA.

Acta Histochem. 2012 Sep;114(5):510-7. doi: 10.1016/j.acthis.2011.09.005. Epub 2011 Oct 13.

PMID:
22000861
31.

Phylogenetic relationships of the algae scraping cyprinid genus Capoeta (Teleostei: Cyprinidae).

Levin BA, Freyhof J, Lajbner Z, Perea S, Abdoli A, Gaffaroğlu M, Ozuluğ M, Rubenyan HR, Salnikov VB, Doadrio I.

Mol Phylogenet Evol. 2012 Jan;62(1):542-9. doi: 10.1016/j.ympev.2011.09.004. Epub 2011 Sep 22.

PMID:
21967785
32.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096
33.

CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.

Farina HG, Benavent Acero F, Perera Y, Rodríguez A, Perea SE, Castro BA, Gomez R, Alonso DF, Gomez DE.

Exp Cell Res. 2011 Jul 15;317(12):1677-88. doi: 10.1016/j.yexcr.2011.04.011. Epub 2011 May 1.

PMID:
21565189
34.

Phylogenetic relationships and biogeographical patterns in Circum-Mediterranean subfamily Leuciscinae (Teleostei, Cyprinidae) inferred from both mitochondrial and nuclear data.

Perea S, Böhme M, Zupancic P, Freyhof J, Sanda R, Ozuluğ M, Abdoli A, Doadrio I.

BMC Evol Biol. 2010 Aug 31;10:265. doi: 10.1186/1471-2148-10-265.

35.

Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.

Rodríguez-Ulloa A, Ramos Y, Gil J, Perera Y, Castellanos-Serra L, García Y, Betancourt L, Besada V, González LJ, Fernández-de-Cossio J, Sanchez A, Serrano JM, Farina H, Alonso DF, Acevedo BE, Padrón G, Musacchio A, Perea SE.

J Proteome Res. 2010 Oct 1;9(10):5473-83. doi: 10.1021/pr100728v.

PMID:
20804217
36.

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P.

BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146.

37.

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.

Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Mol Cancer Ther. 2009 May;8(5):1189-96. doi: 10.1158/1535-7163.MCT-08-1056. Epub 2009 May 5.

38.

Critical care nutrition for feline patients.

Perea SC.

Top Companion Anim Med. 2008 Nov;23(4):207-15. doi: 10.1053/j.tcam.2008.08.001. Review.

PMID:
19081555
39.

Molecular phylogeny and biogeography of the Cuban genus Girardinus Poey, 1854 and relationships within the tribe Girardinini (Actinopterygii, Poeciliidae).

Doadrio I, Perea S, Alcaraz L, Hernandez N.

Mol Phylogenet Evol. 2009 Jan;50(1):16-30. doi: 10.1016/j.ympev.2008.09.014. Epub 2008 Sep 30.

PMID:
18854217
40.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25.

PMID:
18575815
41.
42.

Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.

Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O, Gómez DE, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Int J Cancer. 2008 Jan 1;122(1):57-62.

43.

[Presence of Fusarium oxysporum in induced sputum from a patient with heatstroke. Case report.].

Valverde JF, Del Palacio A, Echave-Susaeta J, Arribi A, Perea S.

Rev Iberoam Micol. 1997 Sep;14(3):138. Spanish. No abstract available.

44.

Onychomycosis: a prospective survey of prevalence and etiology in Madrid.

del Palacio A, Cuétara MS, Garau M, Perea S.

Int J Dermatol. 2006 Jul;45(7):874-6. No abstract available.

PMID:
16894673
45.

Comparison of DNA-based typing methods to assess genetic diversity and relatedness among Candida albicans clinical isolates.

López-Ribot JL, McAtee RK, Kirkpatrick WR, Perea S, Patterson TF.

Rev Iberoam Micol. 2000 Jun;17(2):49-54.

46.

Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.

Perea S, Hidalgo M.

Clin Lung Cancer. 2004 Dec;6 Suppl 1:S30-4. Review.

PMID:
15638955
47.

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M.

Cancer Res. 2004 Dec 15;64(24):9139-43. Erratum in: Cancer Res. 2007 Aug 15;67(16):7937. Cusati, George [corrected to Cusatis, George].

48.

[Bipolaris australiensis in a Spanish patient with allergic chronic sinusitis].

del Palacio A, Pérez-Simón M, Arribi A, Valle A, Perea S, Rodriguez-Noriega A.

Rev Iberoam Micol. 1997 Dec;14(4):191-3. Spanish.

49.

[Invasive maxilar sinusitis by Rhizopus oryzae].

Perea S, del Palacio A, Gil R, de la Serna J, Mata R, Arribi A.

Rev Iberoam Micol. 1997 Dec;14(4):188-90. Spanish.

50.

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, López E, Falcón V, Alonso DF.

Cancer Res. 2004 Oct 1;64(19):7127-9.

Supplemental Content

Support Center